Similarly, MIR126 was found to suppress tumours by directly targeting the insulin receptor substrate-1 (IRS1) [12–14] and the disintegrin- and metalloproteinase domain-containing protein-9 (ADAM9) [15]. The gene discussed is IRS1; the disease is neoplasm.